Grant name: RFA-HL-26-017
Funding organization: National Institutes of Health (NIH)
Total funding amount: Up to $4,466,000 per fiscal year
Duration: Maximum project period of 3 years, with up to 2 years for R61 phase and up to 2 years for R33 phase
Primary objective: Support early-stage translational research for therapeutic candidates targeting HLBS diseases
Funding source: NIH, specifically NHLBI
Significance: Aims to advance projects to meet entry criteria for NHLBI Catalyze Preclinical program
Grant frequency: Recurring
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Small Businesses
Local Governments
State Governments
County Governments
City or Township Governments
Indian/Native American Tribal Governments (Federally Recognized)
Indian/Native American Tribal Governments (Other than Federally Recognized)
Non-domestic (non-U.S.) entities are not eligible to apply, but non-domestic components of U.S. organizations are allowed.
Heart, lung, blood, and sleep diseases and disorders
Identification and characterization of therapeutic candidates
Development of a robust data set for further funding applications
Project management processes to guide studies
Milestone-driven project management
Maximum budget: $400,000 per year for both R61 and R33 phases
Cost matching: Minimum of 0.25:1 non-Federal cash match for R33 phase
Open Date: January 11, 2025
Application Due Dates: Various dates from February 2025 to December 2027
Must comply with NIH Grants Policy Statement
No clinical trials allowed
Detailed project management plan including milestones and timelines
IP and regulatory strategies attachment